×
Akero Therapeutics EBIT 2019-2024 | AKRO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Akero Therapeutics ebit from 2019 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Akero Therapeutics EBIT 2019-2024 | AKRO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Akero Therapeutics ebit from 2019 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$178.9B
Regeneron Pharmaceuticals (REGN)
$125.5B
Vertex Pharmaceuticals (VRTX)
$122.4B
Gilead Sciences (GILD)
$104.4B
Bristol Myers Squibb (BMY)
$100.8B
CSL (CSLLY)
$96.8B
GSK (GSK)
$87.9B
Alnylam Pharmaceuticals (ALNY)
$35.1B
Argenex SE (ARGX)
$31.6B
Biogen (BIIB)
$28.8B
BioNTech SE (BNTX)
$27.5B
Moderna (MRNA)
$26.9B
Illumina (ILMN)
$20.9B
BeiGene (BGNE)
$19.2B
Genmab (GMAB)
$17.3B
BioMarin Pharmaceutical (BMRN)
$13.5B
Vaxcyte (PCVX)
$13B
Exact Sciences (EXAS)
$12.8B
Incyte (INCY)
$12.6B
Insmed (INSM)
$12.5B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.9B
QIAGEN (QGEN)
$10.4B
Bio-Rad Laboratories (BIO.B)
$9.1B
Legend Biotech (LEGN)
$9.1B
Roivant Sciences (ROIV)
$8.9B
Ascendis Pharma (ASND)
$8.7B
Repligen (RGEN)
$8B
Intra-Cellular Therapies (ITCI)
$7.9B
Halozyme Therapeutics (HALO)
$7.9B